bristol-myers glp-1 receptor agonist products Bristol Myers Squibb Clinical Recommendations to Manage Gastrointestinal

And another GLP-1 pill for weight loss is also on its way: Eli Lilly, maker of Zepbound and Mounjaro and a Novo Nordisk competitor, is developing a tablet called orforglipron, which is expected to receive FDA approval this spring.

In a 32-week phase 2 trial investigating the effect of CagriSema on HbA1c in subjects with T2D and BMI 27 kg/m 2 , investigational drug is superior to cagrlintide 2.4 mg alone (-2.2% v -0.9%), but not compared to semaglutide 2.4 mg alone (-1.8%) (75)

Current human studies have not shown an increased overall cancer risk with GLP-1 medications

2024, doi: 10.1038/s41591-024-02996-7

Diabetes Care 46 , 384390 (2023)